The U.S. will buy 2 million doses of an HIV prevention drug for low

The U.S. will purchase 2 million doses of a groundbreaking twice-yearly HIV prevention shot for distribution in low-income countries by 2028.

The drug lenacapvir nearly eliminated new infections in trials, offering superior protection compared with daily pills that patients often forget.

The initiative addresses gaps left by foreign aid cuts that forced clinic closures and disrupted HIV care in hard-hit nations.

WASHINGTON — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.

Gilead Sciences had already announced it would sell that supply of the protective drug lenacapvir at no profit for use in low- and middle-income countries that are hard-hit by HIV. T